NSE: SENORES · BSE: 544319 · ISIN INE0RB801010
Senores Pharmaceuticals Limited stock analysis
Senores Pharmaceuticals Limited ranks #427 in the TickerSutra evidence-ranked universe with a score of 65/100 and 85% data confidence. The latest captured fundamentals show ROCE of 15.1%, quarterly sales growth of 30.6% and quarterly profit growth of 55.7%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- 162.5% three-year sales CAGR
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
Risks and constraints
- CFO/EBITDA is below 0.6×
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹14cr | ₹2cr | ₹1cr | 14.0% |
| 2023 | ₹35cr | ₹13cr | ₹8cr | 36.0% |
| 2024 | ₹215cr | ₹42cr | ₹33cr | 19.0% |
| 2025 | ₹398cr | ₹90cr | ₹58cr | 23.0% |
| 2026 | ₹633cr | ₹168cr | ₹122cr | 27.0% |
| TTM | ₹688cr | ₹201cr | ₹131cr | 29.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Senores Pharmaceuticals Limited has informed the Exchange regarding Scrutinizer Report and Voting results of 09th Annual General Meeting
RoutineSenores Pharmaceuticals Ltd - 544319 - Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportBSE · 28 Sept 2026Senores Pharmaceuticals Limited has informed the Exchange regarding Scrutinizer Report and Voting results of 09th Annual General Meeting
RoutineShareholders meetingNSE · 25 Sept 2026Senores Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026
RoutineSenores Pharmaceuticals Ltd - 544319 - Shareholder Meeting / Postal Ballot-Outcome of AGMBSE · 25 Sept 2026Proceedings of the 9th Annual General Meeting of the Company held on September 25, 2026
RoutineSenores Pharmaceuticals Ltd - 544319 - Clarification On Movement In VolumeBSE · 21 Sept 2026Clarification Letter on volume movement in the scrip of the Company
MANAGEMENT COMMENTARY
Signals from filed documents
Current Ratio 1.92 3.00 (36.00) Due to IPO, Fund utilisation, which was earlier parked as fixed deposits. Debt-Equity Ratio 0.35 0.38 (6.68) - Operating Profit Margin (%) 28.92 22.83 26.64 Improved profitability has led to improvement in margin. Net Profit Margin (%) 19.21 14.00 37.21 Due to significant increase in revenue from operations.
To further support our trajectory, we are progressing towards obtaining European PIC/S approval for our Chhatral manufacturing facility by Q2, Q3. This certification will significantly enhance our regulatory credentials and provide access to key mid-tier markets like Vietnam, South Africa and few more. This will expand our addressable market, create new product registration opportunities, support the next phase of gr
That will further give us considerable amount of sales going forward. Coming to emerging markets, we've what we've told is we have 500-odd product approval today that we have and we have about 900-odd more registrations that are already in pipeline, which are already filed with the MOH. So that will again further significantly increase our revenue as more and more registration approval will come in.
Strengths Strength 1 Our strengths include: Distinct specialty and complex product portfolio built in a short span for Regulated Markets Strong R&D capabilities driving differentiated portfolio of products Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets Professional and dedicated management teams for the diverse business verticals Presence in the Emerging Markets with portfolio
So, there are lot of things that have happened, right? So that's a strategic rationalization as a management we took a call and we thought that this could be a better use of our proceeds than creating a completely new greenfield facility and then wait it out for it to scale up and create the opportunities for us. Again, as I said, that's still a good part of our strategic focus, not that we are going away, but this i
These capabilities make Atlanta an important hub for our CDMO operations targeting regulated markets. Atlanta Facility, United States Three Advanced Manufacturing Lines 1.5 Bn units Annual Installed Capacity 185,300 square feet Total Area Focus on oral solid dosage (OSD) products Vadodara Facility, Gujarat, India Our Apnar Pharma plant further strengthens our finished dosage manufacturing capabilities, providing a mo
These investments are creating a scalable platform that positions us well to capture emerging opportunities across markets. Our proven ability to identify niche opportunities, develop differentiated products and navigate complex regulatory pathways paired with a diversified portfolio and expanding global presence gives us a sustainable edge. As healthcare systems seek distinct solutions, we are positioned to outperfo
This has enabled us to navigate market uncertainties effectively, capitalize on emerging opportunities and continue creating sustainable value for our stakeholders. Senores Pharmaceuticals Limited July 27, 2026 Page 3 of 17 As we enter the next phase of growth, we remain confident in our ability to sustain this momentum, strengthen our competitive positioning and deliver consistent profitable growth over the long ter
We plan to launch 30 approved ANDAs covering more than 100 product strengths, with 4 - 5 new product launches anticipated every quarter. Our R&D pipeline remains robust, with 27 products under development, of which 6 have already been filed and are pending approval. In other mid-tier markets, we currently have 5 products approved, 10 filed, and a further 111 products to be filed over the next year.
I understand H2 would be heavy, but on the GM level, gross margin level, is there any difference between quarter four and quarter one? Because I understand H2 would be heavy, so fixed cost absorption would be much higher, but on the GM level what is your view? Senores Pharmaceuticals Limited July 27, 2026 Page 12 of 17 Sanjay Majmudar: Please understand there are two things.
The year has been defined by meaningful progress across our business. We have continued to expand our capabilities, strengthen our operational foundation, deepen our presence across domestic and international markets, and advance our strategic priorities with discipline and clarity. Our focus has remained firmly on creating a resilient and scalable organization, supported by greater efficiency, technology-led process
Our entry into API manufacturing through RPL, now integrated into the Company, marks an important step toward creating a more connected platform across formulations and critical raw materials. This backward integration strategy is designed to improve supply resilience, quality control, cost efficiency, and responsiveness while reducing dependence on external API suppliers. By securing greater control over key inputs,
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…